Surgical Innovations (SUN)
SURGICAL INNOVATIONS | Directors Dealings And Issue Of Equity | RNS
Surgical Innovations Group plc
("SI" or the "Company")
Directors' dealings and issue of equity
Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that, following the exercise of options by two Directors today, it has issued and allotted 1,500,000 ordinary shares of 1p each.
Details of the Director's options exercised and resulting shareholding is as follows:-
Number of options
Total shareholding following issue
Total shareholding percentage of enlarged issued share capital
Accordingly Application has been made to the London Stock Exchange for the 1,500,000 New Ordinary Shares of 1p each to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur on 24 December 2012. The new ordinary shares rank pari passu with the existing shares of the Company.
Following Admission the total number of ordinary shares in issue will be 404,591,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.
- ENDS -
Surgical Innovations Group plc
Doug Liversidge, Non-Executive Chairman
Tel: +44 (0) 113 230 7597
Graham Bowland, Chief Executive Officer
Seymour Pierce Limited
Mark Percy (Corporate Finance)
Tel: +44 (0) 20 7107 8000
David Banks (Corporate Broking)
Walbrook PR Ltd
Tel: +44 (0) 20 7933 8780
Mob: 07980 541 893 or email@example.com
Mob: 07584 391 303 or firstname.lastname@example.org
Notes to Editors:
About Surgical Innovations Group plc
Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets.
As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.
Over 120 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.
The Group's patented products are sold through three main channels:
Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent.
OEM and IP
The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees. Clients include Teleflex Medical, Olympus and CareFusion.
SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime.
This information is provided by RNS